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Chicken Coop-Induced Hemophagocytic Lymphohistiocytosis
Ahmed E. Kazem D.O., Odaliz Abreu-Lanfranco M.D., Department of Internal Medicine
Henry Ford Health System, Detroit, Michigan
Introduction
• Hemophagocytic Lymphohistiocystosis (HLH) is a rare and often fatal
condition
• It is characterized by an overactive but ineffective response of the
immune system
• There have been several documented causes of HLH, which include
genetic predisposition, malignancy, infection, autoimmune disease and
chronic immunosuppressive therapy
• Due to its non-specific presentation, HLH is often under-recognized,
severely aggressive, and associated with high mortality rates

Case Presentation
• A 42-year-old woman with a two-year history of ankylosing spondylitis,
who was recently initiated on Infliximab, presented with abdominal pain,
fevers, and jaundice.
• She was found to have a temperature of 104F and was noted to have
leukocytosis.
• She was suspected to have acute cholangitis and was initially treated with
antibiotics, however, several imaging studies, including ultrasound,
HIDA, and MRCP did not appreciate intra or extra hepatic duct dilatation,
bile duct wall thickening, or cholelithiasis/choledocholithiasis.
• Her clinical condition worsened, progressing to renal failure, cerebral
edema and new onset seizures. She remained febrile and had persistent
elevation of her liver enzymes and bilirubin.
• Liver biopsy was obtained and demonstrated acute granulomatous
hepatitis secondary to fungal organisms, morphologically consistent with
histoplasmosis (figure 1).
• Interestingly, further history from the patient revealed that she had been
maintaining a chicken coop in her back yard for the past several years and
may have been the source of Histoplasma capsulatum.

Case Presentation (continued)
• Due to persistent fevers, cytopenia and a ferritin level of greater than
20,000, the suspicion for HLH continued to grow
• Bone marrow biopsy was performed which noted hemophagocytic cells
(figure 3), as well as fungal yeast forms, seen with use of GMS stain.
• This patient ultimately was found to have met six of the eight diagnostic
criteria for HLH as documented in Table 1 [fever, bi-cytopenia,
hypertriglyceridemia, elevated ferritin, elevated soluble IL-2 receptor,
and hemophagocytosis on bone marrow biopsy]
• She was started on Amphotericin B for treatment of disseminated
histoplasmosis, as well as Etoposide (total two doses) and
Dexamethasone for treatment of HLH.
• Her clinical condition improved, and within three weeks of initial
diagnosis of HLH, she was ultimately discharged home with continued
anti-fungal treatment with Itraconazole, as well as a four-week taper of
Dexamethasone.

Discussion
• HLH is a rare but potentially fatal disease, characterized by
persistent immune activation and cytokine release, stimulating
bone marrow macrophages to engulf hematopoietic cells
• This case illustrates a patient, who after initiation of treatment
with an anti-TNF agent for ankylosing spondylitis, developed
HLH due to disseminated infection with Histoplasma capsulatum
• Due to its aggressive nature, it is crucial to identify the underlying
insult for triggering HLH, as it will determine which therapeutics
to seek.
• Diagnosis of the disease is outlined in table 1
• Recommended within the Histiocyte Society HLH-2004
guidelines, the current standard treatment for HLH entails
initiating cytotoxic chemotherapy and prospective bone marrow
transplant. However, as described in our case, prompt diagnosis
and directed treatment to the underlying cause of HLH, may
improve outcomes in patients with this fatal condition.
• Interestingly, case reports have shown that patient’s receiving
anti-tumor necrosis factor-alpha therapy, with drugs including
Infliximab, have an increased risk of developing disseminated
infections with Histoplasma capsulatum.
• Our case presents the importance of having prompt recognition of
HLH in patients with non-specific constitutional symptoms such
as fever and fatigue and in patients whose origin of fever remains
unknown. Especially in patients who are immunocompromised,
assessment of serum ferritin level may aid in the diagnosis of
HLH.

• Figure 2. Micrograph depicting hematopoetic cells within
macrophages as described in cases of HLH.
(retrieved from
https://en.wikipedia.org/wiki/Hemophagocytic_lymphohistiocytosis)

Diagnostic Criteria of HLH
Molecular diagnosis consistent with HLH; mutations of PRF1, UNC13D,
Munc18-2, Rab27a, STX11, SH2D1A, or BIRC4
OR
(B) 5 of the 8 criteria listed below to be fulfilled:
1. Fever > 38.5C
2. Splenomegaly

Figure 3. Example of a bone marrow biopsy showing significant
hemophagocystosis. (retrieved from

3. Cytopenias (affecting 2 of 3 lineages in peripheral blood)

http://www.haematologica.org/content/103/10/1635)

4. Hypertriglyceridemia (>265 mg/dL) or Hypofibrinogenemia (<150 mg/dL)
5. Hemophagocytosis in bone marrow, spleen, lymph nodes, or liver
6. Low or absent NK-cell activity
• Figure 1. Example of liver biopsy in patient with disseminated
histoplasmosis. Portrayed is an example of the granulomas that may
form that consist of focal accumulations of macrophages. (retrieved
from https://basicmedicalkey.com/histoplasmosis-6/)

7. Ferritin >500 ng/mL
8. Elevated sCD25 (IL-2 receptor)
Table 1. Histiocyte Society HLH-2004 criteria for diagnosing HLH
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